GlaxoSmithKline plc (GSK)


NYSE - NYSE Real Time Price. Currency in USD
43.42-0.16 (-0.37%)
At close: 4:02 PM EDT
People also watch:
AZNNVSSNYLLYBMY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open43.20
Prev Close43.58
Bid42.90 x 200
Ask43.65 x 200
Day's Range43.18 - 43.53
52wk Range37.24 - 45.58
1y Target EstN/A
Market Cap105.53B
P/E Ratio (ttm)2,713.75
Beta1.05
Volume2,098,741
Avg Vol (3m)3,084,321
Dividend & Yield2.20 (5.06%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • TheStreet.com13 hours ago

    5 Stocks to Sell Now Before It's Too Late

    These stocks could be toxic to your portfolio in the month ahead.

  • Financial Times2 days ago

    [$$] GSK's 'fiercely competitive' Emma Walmsley faces test of experience

    To most people who have encountered Emma Walmsley, her appointment this week as the next head of GlaxoSmithKline, the UK drugmaker, will probably come as little surprise. "She's ruthlessly ambitious," ...

  • Reuters2 days ago

    Hard to swallow: emerging markets get tougher for drugmakers

    Emerging markets have lost their luster for Big Pharma making drug firms ever more dependent on the United States for growth just as American anger over high medicine prices is building. A few years ago, the developing world was seen as a savior as patent after patent expired across the United States and Europe, but emerging market sales growth at the top drug firms slowed to less than two percent in the latest quarter. Forecasts from independent experts IMS Health now suggest the United States will account for 55 percent of sales growth between 2016 and 2020, with emerging markets only contributing 30 percent.